tiakis Biotech AG Receives Positive Scientific Advice from the U.S. FDA for Planned Phase II Trial of Tiprelestat
Stanford University are preparing for a Phase II in Pulmonary Arterial Hypertension (PAH)Kiel, Germany, January 8, 2025 – tiakis ...
Medscape22h
New Trial Seeks to Pin Down Pediatric PAH Treatment
PAH is a rare condition in children, but is often fatal if left untreated, and protocols for pediatric patients have not been ...
Medpage Today on MSN10d
Have the New Pulmonary Hypertension Drugs Changed the Game?
In March, we reported on back-to-back FDA approvals for two treatments in pulmonary arterial hypertension (PAH). In this ...
The American Journal of Managed Care4d
High Uric Acid Appears to Have Causal Role in PAH
A Mendelian analysis supports the idea that hyperuricemia may be an important risk factor for pulmonary arterial hypertension ...
Tectonic Therapeutic: Protein Engineering Platform For GPCRs
Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...
The American Journal of Managed Care9d
Top 5 Most-Read PAH Articles of 2024
The top articles about pulmonary arterial hypertension (PAH) in 2024 included FDA approvals, the effect of salt substitutes ...
AliveGen Receives FDA Orphan Drug Designation for ALG-801 for Pulmonary Arterial Hypertension
AliveGen USA Inc. (AliveGen), a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALG-801 for the ...
Pharmaceutical Technology2d
Cibotercept by Keros Therapeutics for Pulmonary Arterial Hypertension: Likelihood of Approval
Cibotercept is under clinical development by Keros Therapeutics and currently in Phase II for Pulmonary Arterial Hypertension.